The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Concurrent mutations in DNA damage repair genes BRCA1, POLE, ATM and FANCA to predict overall and progression-free survival for patients (pts) with metastatic pancreatic ductal adenocarcinoma (mPDAC) treated with chemotherapy in combination with dual checkpoint inhibition in the CCTG randomized PA.7 trial.
 
Daniel Renouf
Honoraria - Bayer; Ipsen; Roche
Consulting or Advisory Role - Bayer; Merck; Roche
Research Funding - Bayer; Roche (Inst)
 
James Topham
No Relationships to Disclose
 
Jonathan Loree
Consulting or Advisory Role - Advanced Accelerator Applications; AMGEN; Bayer; Guardant Health; Ipsen; Merck; Roche; Taiho Pharmaceutical
Research Funding - Ipsen (Inst); Personalis
 
Dongsheng Tu
No Relationships to Disclose
 
David Schaeffer
Stock and Other Ownership Interests - FOCUS Oncology; Satisfai Health
Honoraria - Amgen; Bayer; Diaceutics; Pfizer
Consulting or Advisory Role - Amgen; Robarts Clinical Trials
 
Jennifer Knox
Honoraria - AstraZeneca; Incyte; Ipsen
Consulting or Advisory Role - AstraZeneca/MedImmune; Incyte; Ipsen
Research Funding - AstraZeneca; Ipsen; Merck
Expert Testimony - AstraZeneca; Incyte
 
Petr Kavan
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb; Eisai; Merck; Novartis; Pfizer; Roche Canada; Taiho Pharmaceutical
 
Derek Jonker
Research Funding - Amgen (Inst); Arcus Biosciences (Inst); AstraZeneca (Inst); BioNTech (Inst); Bold Therapeutics (Inst); Bristol-Myers Squibb (Inst); EMD Serono (Inst); Genentech (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); HotSpot Therapeutics (Inst); Janssen (Inst); Merck (Inst); Mirati Therapeutics (Inst); Ocellaris Pharma (Inst); Pfizer (Inst); Qu Biologics (Inst); RGenta Therapeutics (Inst); RGenta Therapeutics (Inst); SeaGen (Inst)
 
Stephen Welch
Honoraria - Eisai; GlaxoSmithKline; Merck
Consulting or Advisory Role - Amgen; Eisai
 
Felix Couture
Consulting or Advisory Role - Bristol-Myers Squibb; Novartis Canada Pharmaceuticals Inc
 
Frederic Lemay
Consulting or Advisory Role - Astellas Pharma; Bristol-Myers Squibb; Incyte; Ipsen; Medison; Pfizer
Travel, Accommodations, Expenses - Pfizer; Taiho Pharmaceutical
 
Mustapha Tehfe
Honoraria - Bristol-Myers Squibb; Merck; Pfizer; Taiho Pharmaceutical
Consulting or Advisory Role - Bristol-Myers Squibb; Taiho Pharmaceutical
Research Funding - Pfizer Hellas; Taiho Pharmaceutical
 
Mohammed Harb
No Relationships to Disclose
 
Nathalie Aucoin
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Incyte; Merck; Pfizer; Takeda
 
Yoo-Joung Ko
Honoraria - Takeda
Consulting or Advisory Role - Medison
Travel, Accommodations, Expenses - Celgene
 
Patricia Tang
Consulting or Advisory Role - AstraZeneca; Merck; Novartis Canada Pharmaceuticals Inc; Taiho Pharmaceutical
Speakers' Bureau - Apobiologix
Travel, Accommodations, Expenses - Amgen
 
Pan Du
Employment - Predicine
Leadership - Predicine
Stock and Other Ownership Interests - Predicine
 
Shidong Jia
Employment - Genentech (I); Predicine
Leadership - Predicine
Stock and Other Ownership Interests - Predicine
Patents, Royalties, Other Intellectual Property - Liquid biopsy in cancer detection, therapy monitoring, MRD and early cancer detection
 
Sharlene Gill
Honoraria - Amgen; Eisai
Consulting or Advisory Role - Amgen; Bristol-Myers Squibb Canada; Eisai; Ipsen; Merck; Pfizer; Roche Canada
Research Funding - Incyte (Inst)
 
Christopher O'Callaghan
No Relationships to Disclose